Pereira da Silva Anderson Matheus, de Deus Ocílio, Falcão Luciano, Han Mariana Lee, Ribeiro Filipe Virgilio, Machado Magalhães Pedro Lucas, Melo Neto Altair, Meira Othon Trevisan, Bastos Maximiano Mariana Leticia, Noleto Gustavo Sousa, Günkan Ahmet, Jabbour Pascal M
Department of Physiology and pharmacology, Federal University of Pernambuco, Recife, Brazil.
Department of Medicine, Federal University of Piauí, Teresina, Brazil.
Neuroradiology. 2025 Jul 31. doi: 10.1007/s00234-025-03710-1.
The optimal duration of dual antiplatelet therapy (DAPT) following endovascular treatment of intracranial aneurysms remains uncertain. While DAPT effectively prevents thromboembolic complications, prolonged therapy may increase bleeding risk. This systematic review and meta-analysis compared the efficacy and safety of short-term versus long-term DAPT in patients undergoing endovascular treatment with stent-assisted coiling or flow diversion.
We conducted a systematic review and meta-analysis according to PRISMA guidelines. Studies were identified through PubMed, Embase and Cochrane from inception to January 2025. Eligible studies included randomized controlled trials (RCTs) and observational cohorts comparing short-term DAPT (≤ 6 months) with long-term DAPT (> 6 months) in adults treated for intracranial aneurysms. Pooled risk ratio (RR) with 95% confidence intervals (CI) were calculated using a random-effects model. Risk of bias was assessed using RoB 2 for RCTs and ROBINS-I for observational studies.
Seven studies, comprising a total of 17,380 patients, were included, one RCT and six retrospective cohorts. The pooled analysis showed no significant difference in thromboembolic events between short- and long-term DAPT (RR: 1.18; 95% CI: 0.42-3.30; I = 60.5%). Short-term DAPT was associated with a lower risk of major bleeding (RR: 0.54; 95% CI: 0.32-0.91; I = 0%). No significant differences were observed between groups in retreatment (RR: 0.94; 95% CI: 0.24-3.62) or mortality (RR: 3.11; 95% CI: 0.96-10.09).
Short-term DAPT demonstrates similar efficacy to long-term DAPT in preventing thromboembolic events and retreatment, with a lower incidence of major bleeding. These findings suggest that shorter DAPT regimens may offer a favorable safety profile. However, further large-scale RCTs are needed to establish definitive guidelines.
颅内动脉瘤血管内治疗后双重抗血小板治疗(DAPT)的最佳持续时间仍不确定。虽然DAPT能有效预防血栓栓塞并发症,但延长治疗可能会增加出血风险。本系统评价和荟萃分析比较了短期与长期DAPT在接受支架辅助弹簧圈栓塞或血流导向血管内治疗患者中的疗效和安全性。
我们根据PRISMA指南进行了系统评价和荟萃分析。通过PubMed、Embase和Cochrane从创刊至2025年1月检索研究。符合条件的研究包括随机对照试验(RCT)和观察性队列,比较短期DAPT(≤6个月)与长期DAPT(>6个月)在接受颅内动脉瘤治疗的成人中的情况。使用随机效应模型计算合并风险比(RR)及95%置信区间(CI)。使用RoB 2评估RCT的偏倚风险,使用ROBINS-I评估观察性研究的偏倚风险。
共纳入7项研究,总计17380例患者,1项RCT和6项回顾性队列研究。汇总分析显示,短期和长期DAPT在血栓栓塞事件方面无显著差异(RR:1.18;95%CI:0.42 - 3.30;I² = 60.5%)。短期DAPT与较低的大出血风险相关(RR:0.54;95%CI:0.32 - 0.91;I² = 0%)。两组在再次治疗(RR:0.94;95%CI:0.24 - 3.62)或死亡率(RR:3.11;95%CI:0.96 - 10.09)方面未观察到显著差异。
短期DAPT在预防血栓栓塞事件和再次治疗方面显示出与长期DAPT相似的疗效,且大出血发生率较低。这些发现表明较短的DAPT方案可能具有良好的安全性。然而,需要进一步的大规模RCT来制定明确的指南。